OP25.06: Maternal serum ADAM 12 levels in Down syndrome pregnancies during the first trimester

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.

Download Full-text

Impact of Ductus Venosus Assessment in Screening Down Syndrome Protocols: An Improved Strategy in a Fetal Medicine Unit

Donald School Journal of Ultrasound in Obstetrics & Gynecology ◽

10.5005/jp-journals-10009-1010 ◽

2009 ◽

Vol 3 (2) ◽

pp. 10-17 ◽

Cited By ~ 1

Author(s):

Mónica Echevarria ◽

Carmen Comas ◽

M Angeles Rodríguez ◽

Joan Nicolau ◽

Bernat Serra ◽

...

Keyword(s):

Down Syndrome ◽

First Trimester ◽

Nuchal Translucency ◽

Serum Biochemistry ◽

Screening Strategy ◽

Maternal Serum ◽

Ductus Venosus ◽

Early Evaluation ◽

Invasive Test ◽

Screening Efficiency

ABSTRACT Objective To estimate the improvement in screening efficiency when ductus venosus (DV) Doppler studies are added to existing Down syndrome (DS) screening protocols. Methods First-trimester combined screening for trisomy 21 was prospectively carried out, from October 2003 to March 2008, in 8842 consecutive singleton pregnancies attended in our tertiary reference center. The nuchal translucency (NT) and the pulsatility index for veins for DV were calculated. The maternal serum biochemistry was measured using the Kryptor analyzer, at the same time of the scan (one step strategy) or before it (two step strategy). The detection rate (DR) and false-positive rates for standard screening strategy (maternal age, NT and biochemistry) and the same strategy but including DV assessment were calculated. Results Successful DV assessment was possible in the 95.3% of cases, representing a total of 8426 cases. Down syndrome was identified in 34 pregnancies (prevalence of DS 1:250). For a fixed screen positive rate of 5%, the addition of the DV assessment improves the DR from 85 to 94% and, for a fixed DR of 85%, it reduces the number of unnecessary invasive tests from 3.7 to 3.2%. Conclusion Early evaluation of DV can be introduced to standard DS screening strategies in experienced centers as a first level test to reduce invasive test rate derived from the existing protocols.

Download Full-text

Strong impact of ethnicity on effectiveness of the first trimester maternal serum screen of fetal Down syndrome

The Journal of Maternal-Fetal & Neonatal Medicine ◽

10.1080/14767058.2017.1358264 ◽

2017 ◽

Vol 31 (21) ◽

pp. 2847-2851 ◽

Cited By ~ 1

Author(s):

Thitikarn Lerthiranwong ◽

Chanane Wanapirak ◽

Supatra Sirichotiyakul ◽

Fuanglada Tongprasert ◽

Kasemsri Srisupundit ◽

...

Keyword(s):

Down Syndrome ◽

First Trimester ◽

Maternal Serum ◽

Strong Impact

Download Full-text

Screening for Down syndrome in the first trimester

Reproduction Fertility and Development ◽

10.1071/rd9951413 ◽

1995 ◽

Vol 7 (6) ◽

pp. 1413 ◽

Cited By ~ 1

Author(s):

KJ Powell ◽

JG Grudzinskas

Keyword(s):

Down Syndrome ◽

First Trimester ◽

Maternal Blood ◽

Maternal Serum ◽

Published Data ◽

Maternal Serum Screening ◽

Ultrasound Findings ◽

Serum Screening ◽

Associated Proteins ◽

Trimester Screening

Second-trimester maternal serum screening for Down syndrome is now well established, and permits detection of up to 70% of cases. The disadvantage of this sort of screening is that the timing of maternal blood sampling is relatively late (after 15 weeks). There is an accumulating body of evidence to suggest that in the first trimester concentrations of a number of pregnancy-associated proteins and hormones differ in chromosomally normal and abnormal pregnancies. A first-trimester maternal serum screening test for Down syndrome may therefore be possible. In addition, new methods of screening have recently been described based on ultrasound findings at 11 to 13 weeks of gestation. This review article presents a discussion of published data on the feasibility of first-trimester screening for Down syndrome.

Download Full-text